Hepatocellular adenoma (HCA) is a rare benign epithelial neoplasm with potential for hemorrhage, rupture, or malignant transformation. Reported annual incidence of HCA is approximately
INTRODUCTION
Hepatocellular adenoma (HCA) is a rare and incompletely understood benign epithelial tumor. Among women who have never used contraceptives, the incidence of HCA is estimated at approximately one per 1,000,000 person-years; with oral contraceptives, the annual incidence is approximately 30 per 1,000,000 person-years. Among men, the incidence is even lower. 1 In addition to oral contraceptive or androgen use, other risk factors include type I and III glycogen storage diseases, external androgens, antiepileptic drugs, and nonalcoholic fatty liver disease. [1] [2] [3] [4] [5] In the general population, the most common HCA subtype is steatotic, reflecting hepatocyte nuclear factor 1A inactivation. 6 The risks of rupture or malignant transformation of HCA are substantial and may be increased during pregnancy or with ongoing use of oral contraceptives. As a result of these risks, HCA is usually managed with resection, embolization, or close radiographic follow-up. 7 Childhood cancer survivors are at risk for a small number of hepatic late effects. Most notably, hepatic hemochromatosis may be acquired due to red blood cell transfusion requirements during treatment. 8 In addition, survivors treated before routine screening of the blood supply are at risk for hepatitis C infection. Finally, a possible increased risk of focal nodular hyperplasia has been identified among childhood cancer survivors, although the literature is sparse. 9 An increased risk for HCA has not been described.
Abbreviations: HCV, hepatocellular adenoma; MSK, Memorial Sloan Kettering
METHODS
Following approval by the Institutional Review Board at Memorial Sloan Kettering (MSK), a comprehensive search of the medical record was initiated. Pathology reports, visit notes, histology codes, and billing diagnosis codes were searched for the terms "hepatic adenoma," "hepatocellular adenoma," "hepatobiliary adenoma," "hepatoma," or "hepadenoma." Once patients with HCA were identified, demographics, cancer diagnosis, and cancer treatment variables were collected from the medical chart. Those with slides or tissue available were rereviewed by a gastrointestinal pathologist at MSK (JS).
Cases were compared to HCA from the general population using literature review. However, due to the small number of cases and lack of an appropriate control (nonsurvivor) population, no attempts at statistical analysis or comparisons were made.
RESULTS
Among adult survivors of childhood and young adult cancer followed at this large U.S. cancer center, 12 cases of HCA were confirmed; seven patients (58%) had more than one adenoma. Six cases were initially identified from the 1,296 patients followed in the Adult Long-Term 
Clinical characteristics and outcomes
Among these 12 childhood and young adult cancer survivors with HCA, only one patient was male (Table 1) . Importantly, this patient also had a history of hematopoietic stem cell transplant for acute myelogenous leukemia and was hypogonadal. At the time of his biopsy, he was being treated with androgen replacement, a known risk factor for HCA. Due to the clinical circumstances, it was not felt appropriate to discontinue androgen replacement. Among the 11 female survivors with HCA, all had a history of current or prior treatment with estrogen and progesterone. Eight of 12 patients (67%) had hypothyroidism and two (17%)
were taking antiepileptic drugs.
The most common cancer diagnosis was leukemia (N = 4; 33%). 
Pathology review
Pathology reports of all 12 cases were reviewed. In addition, slides of six cases were available and all six were re-examined at the time of this study. The results of slide re-examination were concordant with the pathology reports in all six cases. The diagnosis of HCA was confirmed in all cases. Upon histological assessment, four of the 12 adenomas were subtyped as inflammatory, three as steatotic, and five as unclassified, noninflammatory (Fig. 1) . The nonneoplastic liver was normal in 10 cases, and showed steatosis without fibrosis in two cases.
Follow-up
Only two patients (17%) were monitored radiographically without other intervention following biopsy. Seven patients (58%) underwent hepatic resection, of which four had residual adenoma following surgery and continue to be monitored with MRI. Three (25%) underwent transarterial embolization (without chemotherapy) via interventional radiology. Two female patients had their hormone replacement formulation changed to transdermal in an effort to reduce hepatic estrogen exposure; in other patients, estrogen and 
DISCUSSION
We describe herein 12 cases of HCA among adult survivors of childhood and young adult cancer followed at a large U.S. cancer center.
In this setting, HCAs were found to be large, often multiple, and primarily inflammatory, without steatosis. No prior study has identified an increased risk for HCA following childhood and young adult cancer therapy.
As in other populations, the majority of our patients with HCA were female with a history of estrogen therapy. 1 Yet, the mechanism by which estrogen increases the risk of HCA in a noncancer setting is poorly understood. 10 Furthermore, young women who are postmenopausal as a result of their cancer treatment have strong indications for estrogen and progesterone replacement and may not be able to easily discontinue therapy. 11 Screening for HCA among young hypogonadal cancer survivors may be warranted, but further study of this question is needed.
Some aspects of our case series suggest that new mechanisms may be involved in HCA incidence in this population. One-third of these HCA cases were of the inflammatory subtype, which is not the predominant subtype in the general population. 6 Typically, the inflammatory subtype is associated with gain of function IL-6 signal transducer (IL6ST;gp130) and STAT3 mutations. 10 Although persistent activation of this signaling pathway is associated with tumorigenesis, 12 other work suggests that HCA of the inflammatory subtype do not progress to carcinoma. 6 Therefore, whether HCA among cancer survivors will be at increased or decreased risk for malignant transformation remains to be determined.
Because only cases were captured in this brief report, and a suitable control group that would have undergone routine imaging has been difficult to identify, comparisons are limited and incidence or prevalence could not be calculated.
Nonetheless, a small number of clinical and treatment variables were found to be common among survivors with HCA: (1) female gender, (2) history of stem cell transplant, (3) hormone replacement therapy, and (4) TBI. Importantly, HCA has the potential to be extremely morbid; ten of 12 identified survivors required major intervention (surgery or embolization) and four of these were left with residual adenoma requiring ongoing monitoring. Thus, further study to clarify risk, mechanism, and modifying factors in this population is warranted.
